Syndax Pharmaceuticals Inc
$ 17.34
-3.77%
05 Jun - close price
- Market Cap 1,536,498,000 USD
- Current Price $ 17.34
- High / Low $ 18.13 / 17.11
- Stock P/E N/A
- Book Value 0.47
- EPS -2.79
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -1.90 %
- 52 Week High 25.59
- 52 Week Low 8.59
About
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$39.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-26 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-03-03 | 2024-11-05 | 2024-08-01 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.48 | -0.78 | -0.7 | -0.83 | -0.98 | -1.1 | -0.98 | -0.8 | -0.85 | -1 | -0.73 | -0.64 |
| Estimated EPS | -0.59 | -0.5854 | -0.71 | -1.01 | -1.27 | -0.2289 | -1.06 | -0.91 | -0.98 | -0.97 | -0.8 | -0.75 |
| Surprise | 0.11 | -0.1946 | 0.01 | 0.18 | 0.29 | -0.8711 | 0.08 | 0.11 | 0.13 | -0.03 | 0.07 | 0.11 |
| Surprise Percentage | 18.6441% | -33.2422% | 1.4085% | 17.8218% | 22.8346% | -380.5592% | 7.5472% | 12.0879% | 13.2653% | -3.0928% | 8.75% | 14.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNDX
2026-06-05 07:10:28
Syndax Pharmaceuticals announced a private placement of $250 million in 2.25% Convertible Senior Notes due 2031. The notes convert at an initial rate of 40.3894 shares per $1,000 principal, with a conversion price of $24.76, representing a 35% premium. The company expects to receive approximately $243 million in net proceeds, which will be used for general corporate purposes including R&D, commercialization, and business development efforts.
2026-06-04 15:01:00
Syndax Pharmaceuticals announced inducement awards on June 1, 2026, granting stock options to four new employees to purchase up to 66,700 shares of common stock. These options will vest over four years, with a specific schedule for shares vesting on the one-year anniversary and monthly thereafter, contingent on the employees' continued service. The grants are in accordance with NASDAQ Listing Rule 5635(c)(4) and aim to attract and retain talent.
2026-06-04 12:39:29
Syndax Pharmaceuticals (SNDX) has announced a $250 million convertible senior note offering maturing in 2031, aiming to secure funding for strategic initiatives and development projects. While this move provides a financial boost, the company currently holds a low GF Score™ of 28/100, indicating significant challenges in financial health, including a high debt-to-equity ratio and negative earnings. Investors are advised to proceed with caution due to these financial indicators and recent insider selling activity.
2026-06-04 11:39:29
Syndax Pharmaceuticals has successfully raised $250 million through a private placement of 2.25% Convertible Senior Notes due 2031, expecting net proceeds of approximately $243 million. These unsecured notes, which mature on June 15, 2031, are convertible into common stock at an initial price of about $24.76 per share, representing a 35% premium. The company plans to utilize these proceeds for general corporate purposes, including research and development, commercialization, and business development.
2026-06-04 10:39:29
Syndax Pharmaceuticals (NASDAQ: SNDX) has entered into privately negotiated agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031, with closing expected on June 10, 2026. The estimated net proceeds of approximately $243 million will be used for general corporate purposes, including R&D and commercialization. The notes are senior unsecured, bear semiannual interest, and are initially convertible at a 35% premium to the June 3, 2026 share price, with Syndax having the option to redeem them from June 20, 2029, under certain conditions.
2026-06-03 06:41:23
Syndax Pharmaceuticals highlighted positive data for Revuforj® (revumenib) presented at ASCO 2026, including an oral presentation demonstrating favorable outcomes in acute leukemia patients who resumed revumenib post-transplant. A pooled analysis showed a 2-year overall survival rate of 90% in this high-risk group, significantly higher than historical benchmarks. The company also presented data on revumenib's unique pharmacokinetic profile, indicating its ability to be administered with gastric acid-reducing agents without compromising efficacy.
